Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

LAVA Therapeutics N.V. - Ordinary Shares (NQ:LVTX)

1.740 UNCHANGED
Last Price Updated: 4:00 PM EST, Nov 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.740
Bid (Size) 1.610 (5,000)
Ask (Size) 1.850 (100)
Prev. Close 1.740
Today's Range 1.740 - 1.740
52wk Range 0.8502 - 1.825
Shares Outstanding 26,289,087
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.
From XOMA Royalty Corporation
Via GlobeNewswire
News headline image
LAVA Therapeutics Stock Drops After Amended Deal With XOMA Royalty ↗
As per the amended deal, LAVA shareholders will receive an initial cash payment of $1.04 per share, down from the range of $1.16 to $1.24 initially agreed upon. 
Via Stocktwits

Performance

YTD
N/A
N/A
1 Month
N/A
N/A
3 Month
+7.4%
+7.4%
6 Month
+28.2%
+28.2%
1 Year
+61.1%
+61.1%

More News

Read More
News headline image
XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement
From XOMA Royalty Corporation; LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics Stock Slips 9% Pre-Market – Here’s Why The Company Canceled Its Shareholder Meeting ↗
Via Stocktwits
News headline image
Thursday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
From XOMA Royalty Corporation; LAVA Therapeutics
Via GlobeNewswire
News headline image
4 Biotech Stocks That Are Showing Weakness: Momentum Scores Fading Over The Past Week ↗
Via Benzinga
News headline image
This Block Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗
Via Benzinga
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HilleVax, Inc. (Nasdaq – HLVX), Steelcase Inc. (NYSE – SCS), LAVA Therapeutics N.V. (Nasdaq – LVTX), Arcadia Biosciences, Inc. (Nasdaq – RKDA)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
LVTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lava Therapeutics N.V. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
From XOMA Royalty Corporation; LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang ↗
Via Benzinga
News headline image
This Constellation Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday ↗
Via Benzinga
News headline image
On Wednesday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
News headline image
What's going on in today's session ↗
Via Chartmill
News headline image
Which stocks are experiencing notable movement on Tuesday? ↗
Via Chartmill
News headline image
Traders are paying attention to the gapping stocks in Tuesday's session. ↗
Via Chartmill
News headline image
LVTX Stock Earnings: LAVA Therapeutics Beats EPS for Q2 2024 ↗
Via InvestorPlace
News headline image
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Announces Annual Meeting of Shareholders
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LVTX Stock Earnings: LAVA Therapeutics Beats EPS, Misses Revenue for Q1 2024 ↗
Via InvestorPlace
News headline image
LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
From LAVA Therapeutics N.V.
Via GlobeNewswire
News headline image
LVTX Stock Earnings: LAVA Therapeutics Misses EPS, Misses Revenue for Q4 2023 ↗
Via InvestorPlace

Frequently Asked Questions

Is LAVA Therapeutics N.V. - Ordinary Shares publicly traded?
Yes, LAVA Therapeutics N.V. - Ordinary Shares is publicly traded.
What exchange does LAVA Therapeutics N.V. - Ordinary Shares trade on?
LAVA Therapeutics N.V. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for LAVA Therapeutics N.V. - Ordinary Shares?
The ticker symbol for LAVA Therapeutics N.V. - Ordinary Shares is LVTX on the Nasdaq Stock Market
What is the current price of LAVA Therapeutics N.V. - Ordinary Shares?
The current price of LAVA Therapeutics N.V. - Ordinary Shares is 1.740
When was LAVA Therapeutics N.V. - Ordinary Shares last traded?
The last trade of LAVA Therapeutics N.V. - Ordinary Shares was at 11/20/25 04:00 PM ET
What is the market capitalization of LAVA Therapeutics N.V. - Ordinary Shares?
The market capitalization of LAVA Therapeutics N.V. - Ordinary Shares is 45.74M
How many shares of LAVA Therapeutics N.V. - Ordinary Shares are outstanding?
LAVA Therapeutics N.V. - Ordinary Shares has 46M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.